Jason Madore

Herston, QLD, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications

Common Immunosuppressants Impair Recipient Immunity but Do Not Safeguard Donor Tissue-resident Immunity in Kidney Transplantation.

Common Immunosuppressants Impair Recipient Immunity but Do Not Safeguard Donor Tissue-resident Immunity in Kidney Transplantation.

Journal: Transplantation
Published: July 20, 2026

Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre-Operative PD1 CheckpOint Blockade and Receptor Activator of NF-κB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC)-A Phase 1B/2 Trial.

Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre-Operative PD1 CheckpOint Blockade and Receptor Activator of NF-κB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC)-A Phase 1B/2 Trial.

Journal: Asia-Pacific journal of clinical oncology
Published: August 01, 2025

Type I Interferon Drives a Cellular State Inert to TCR-Stimulation and Could Impede Effective T-Cell Differentiation in Cancer.

Type I Interferon Drives a Cellular State Inert to TCR-Stimulation and Could Impede Effective T-Cell Differentiation in Cancer.

Journal: European journal of immunology
Published: July 09, 2024

Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma.

Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma.

Journal: Leukemia
Published: September 30, 2022

Nicotinamide for skin cancer chemoprevention: effects of nicotinamide on melanoma in vitro and in vivo.

Nicotinamide for skin cancer chemoprevention: effects of nicotinamide on melanoma in vitro and in vivo.

Journal: Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
Published: January 17, 2020

Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.

Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 02, 2019

Tumor intrinsic and extrinsic immune functions of CD155.

Tumor intrinsic and extrinsic immune functions of CD155.

Journal: Seminars in cancer biology
Published: September 26, 2019

CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells.

CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells.

Journal: Immunity
Published: September 25, 2019

Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.

Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.

Journal: Cancer discovery
Published: May 18, 2019

Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells.

Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells.

Journal: Scientific reports
Published: March 10, 2019

Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome.

Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome.

Journal: Oncoimmunology
Published: November 20, 2018

Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment.

Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment.

Journal: Histopathology
Published: November 14, 2018
Showing 1-12 of 44

Last Updated: 09/26/2026